{
  "messages": [
    {
      "role": "system",
      "content": "You are JournalReviewBot, a bot that summarizes and compiles main points from provided medical journals. A user may input a text snippet and ask questions about the text. You are to draw all information and assumptions directly from the text, and from no other internal or external sources. Your responses are to be formatted neatly, with a introduction that briefly summarizes key points before the main focus is presented. Your responses may utilize formatting such as numbered lists or bullet points. You are to maintain a clinical tone for all responses. Your responses should be free of any personal introductions or pleasantries. The response is to explain the information with a cited quotation from the journal, and should be no longer than 250 words. If the provided text is not a medical journal or lacks sufficient information to answer a question, state this clearly and explain what type of content would be needed. When the journal contains highly technical medical terms that are essential to the answer, provide the exact quoted terminology followed by a brief contextual explanation based solely on how the term is used within the provided text. If a user's question is vague or could have multiple interpretations based on the provided text, ask for clarification about which specific aspect they want you to address."
    },
    {
      "role": "user",
      "content": "Patient A is interested in enrolling in a clinical trial. Patient A, female, 49, presents with unifocal, non-lobular invasive carcinoma with a non-cancerous tissue margin of 2.01mm. Patient A is otherwise healthy with no other medical conditions. The patient is node-negative. Is this patient a good fit for IMPORT LOW trial? Patient will be 50 within 6 months. \n\nPatient B is 51, AFAB, has been on hormone replacement therapies before diagnosis. Diagnosis is unifocal, non-lobular invasive carcinoma margin of 4.7mm. The patient seems eligible for the trial but is concerned about relapse rates over 5 years and the impacts of irradiated damaged tissue in the case of a cardiac event. Explain the rates and risks involved. \n\nPatient C is a 52 year old female. Is in remission from unifocal, non-lobular invasive carcinoma margin of 5.7mm, but is interested in contributing to a trial in the future if the cancer returns and wants to know the limitations of the trial. Previously had whole-breast radiation therapy. \n\nComment\n1010 www.thelancet.com Vol 390 September 9, 2017\nGreat improvements in the therapeutic ratio of cancer\ntreatment can result from innovative approaches\nthat maintain tumour control benefits while lowering\ntreatment-associated morbidity. The IMPORT LOW\ntrial by Charlotte Coles and colleagues1\n in The Lancet is a\nhigh-quality randomised trial of treatment de-escalation\nin the multidisciplinary management of breast cancer.\nNumerous trials and their meta-analyses have\nestablished that after breast-conserving surgery,\nradiotherapy cuts the risk of recurrence by half and\nreduces breast cancer mortality.2\n However, this\ntreatment can also result in serious morbidity due to the\nincidental irradiation of normal tissues, including the\nheart, lung, and normal breast.3,4\nPartial-breast irradiation reduces the dose to normal\ntissues by treating only the region surrounding the\ntumour bed (the site of most local failures) rather than\nthe traditional radiotherapeutic target (the whole\nbreast). By reducing the volume of tissue irradiated,\nparticularly when using advanced techniques that\nallow highly conformal dose distributions, the number\nof treatments needed could be reduced by allowing\nhigher doses per treatment fraction than conventionally\nadministered to the whole breast. Indeed, many trials\nhave investigated or are investigating the simultaneous\nreduction in the treatment field and increased radiation\ndose per fraction in an attempt to reduce not only\ntoxicity but also the burden from multiple repeated\ntreatments.5\u20137 By contrast, IMPORT LOW used a relatively\nsimple technique to reduce the volume of treatment,\nwhile holding radiation dose and fractionation constant.\nThe control group received a whole-breast regimen of\n40 Gy radiotherapy daily in 15 fractions. The experimental\ngroups had treatment in the vicinity of the tumour bed\nEarly-stage breast cancer: falling risks and emerging options\nimmunosuppression regimens vary depending on the\norgan. The penis is a complex organ composed of many\ndifferent tissue types including skin, connective tissue,\nvascular sinuses, extensive innervation, and urothelium.\nIt is unclear how these tissues will reject, how rejection\nwill affect its function, how to best monitor the penis\nfor rejection, and which immunosuppression regimen\nis optimal. Indeed, reports suggest that ciclosporine A\nmight impair erectile function, stressing the importance\nof preclinical research in this developing area of VCA.5,9,10\nAdditionally, immune tolerance is an active area of\nresearch11 that seeks to reprogramme the recipient\u2019s\nimmune system to accept donated tissues, with the\ngoal of reducing the amount of, or need for, traditional\nimmunosuppression. Additional research regarding the\nethics and clinical application of penile transplantation,\nincluding the adoption of guidelines, is needed to ensure\nsafe and ethical use. These potential improvements will\nhelp to lower the risks and increase the application of\ntransplantation to address difficult-to-treat conditions.\nNikolai A Sopko, *Arthur L Burnett\nThe James Buchanan Brady Urological Institute and Department\nof Urology, The Johns Hopkins University School of Medicine,\nBaltimore, MD 21287, USA\naburnet1@jhmi.edu\nWe declare no competing interests.\n1 Rodrigue JR, Tomich D, Fleishman A, Glazier AK. Vascularized composite\nallograft donation and transplantation: a survey of public attitudes in the\nUnited States. Am J Transplant 2017; published online May 15. DOI:10.1111/\najt.14302.\n2 van der Merwe A, Graewe F, Z\u00fchlke A, et al. Penile allotransplantation for\npenis amputation following ritual circumcision: a case report with\n24 months of follow-up. Lancet 2017; published online Aug 17.\nhttp://dx.doi.org/10.1016/S0140-6736(17)31807-X.\n3 Kepe T. \u201cSecrets\u201d that kill: crisis, custodianship and responsibility in ritual\nmale circumcision in the Eastern Cape Province, South Africa.\nSoc Sci Med 2010; 70: 729\u201335.\n4 Kayes O, Shabbir M, Ralph D, Minhas S. Therapeutic strategies for patients\nwith micropenis or penile dysmorphic disorder. Nat Rev Urol 2012;\n9: 499\u2013507.\n5 Sopko NA, Tuffaha SH, Lough D, et al. Penile allotransplantation for\ncomplex genitourinary reconstruction. J Urol 2017; 198: 274\u201380.\n6 Tuffaha SH, Cooney DS, Sopko NA, et al. Penile transplantation:\nan emerging option for genitourinary reconstruction. Transpl Int 2017;\n30: 441\u201350.\n7 Massanyi EZ, Gupta A, Goel S, et al. Radial forearm free flap phalloplasty for\npenile inadequacy in patients with exstrophy. J Urol 2013; 190: 1577\u201382.\n8 Callens N, De Cuypere G, Van Hoecke E, et al. Sexual quality of life after\nhormonal and surgical treatment, including phalloplasty, in men with\nmicropenis: a review. J Sex Med 2013; 10: 2890\u2013903.\n9 Sopko NA, Matsui H, Lough DM, et al. Ex vivo model of human penile\ntransplantation and rejection: implications for erectile tissue physiology.\nEur Urol 2017; 71: 584\u201393.\n10 El-Bahnasawy MS, El-Assmy A, El-Sawy E, et al. Critical evaluation of the\nfactors influencing erectile function after renal transplantation.\nInt J Impot Res 2004; 16: 521\u201326.\n11 Leonard DA, Cetrulo CL, McGrouther DA, Sachs DH. Induction of tolerance\nof vascularized composite allografts. Transplantation 2013; 95: 403\u201309.\nPublished Online\nAugust 2, 2017\nhttp://dx.doi.org/10.1016/\nS0140-6736(17)31599-4\nSee Articles page 1048\nDr P Marazzi/Science Photo Library \nComment\nwww.thelancet.com Vol 390 September 9, 2017 1011\nwith the same dose and fractionation (partial-breast\ngroup) and this treatment with the addition of 36 Gy on\nthe remainder of the whole breast (reduced-dose group).\nNotably, their approach differs from the more highly\nconformal approach to partial-breast irradiation that is\nactively being investigated in other trials. Treatment in\nIMPORT LOW involved simple forward planning using\nstandard medial and lateral tangential beams reduced\nin length. This design allows the trial to answer the pure\nquestion of whether a reduction in radiation field is\nsafe, with findings that can be applied to many settings,\nincluding those with low availability of resources or lower\ntechnological capability.\nThe trial shows non-inferiority, with remarkably low\nestimates of local relapse at 5 years (1\u00b71% [95% CI 0\u00b75\u20132\u00b73]\nof patients in the control group, 0\u00b72% [0\u00b702\u20131\u00b72] in the\nreduced-dose group, and 0\u00b75% [0\u00b72\u20131\u00b74] in the partialbreast group). Serious consequences of radiotherapy\nwere uncommon; establishing the effect of irradiating\nreduced volumes of tissues on endpoints such as cardiac\nevents or second malignancy will probably ultimately\nrequire observational comparative effectiveness analyses\nor individual patient-level meta-analyses of the multiple\ntrials investigating partial-breast irradiation. Still, because\nthe trial laudably included assessment of patient-reported\noutcomes, it was possible for IMPORT LOW to show\nthat partial-breast treatment reduced patient-reported\nchanges in breast appearance, providing support for the\nidea that treatment de-escalation in some women is not\nonly safe, but might reduce toxicity.\nThe findings of the trial should, however, only\nbe generalised to women similar to those actually\nenrolled: women aged 50 years or older with small,\nunifocal, non-lobular invasive carcinoma resected with\nnon-cancerous tissue margins of 2 mm or more. Most\nof the women had received endocrine therapy whereas\nfew had received chemotherapy. Most patients enrolled\nwere node negative, and the authors themselves\ncaution against generalising the results of this trial to\nnode-positive patients.\nOngoing research regarding radiotherapy de-escalation\nis still crucial. Even 15 fractions of partial-breast\nradiotherapy is burdensome and has toxicity risks. Mature\ndata from trials investigating partial-breast regimens\nthat can be administered more efficiently are therefore\nimportant, as are trials seeking to identify patients who\nmight safely forego radiotherapy altogether. Indeed,\nperhaps the most striking finding of IMPORT LOW is not\nsimply that of non-inferiority but rather the extremely\nlow absolute recurrence rates observed across all groups,\nwhich were markedly lower than in historical trials.2\nAlthough previous trials have not identified a subgroup of\nwomen in whom adjuvant radiotherapy might safely be\nomitted altogether, with the exception of older women\nwith small hormone-sensitive tumours,8,9 the remarkably\nlow recurrence rates observed in this trial prompt yet again\nthe question of whether some other patients might also\nreasonably omit radiotherapy. Although longer follow-up\nis needed, particularly in patients with favourable disease\nwhose recurrences might develop late, the findings of\nIMPORT LOW support ongoing efforts in the UK, the USA,\nand beyond that aim to establish whether improvements\nin other disciplines (eg, imaging, pathology, surgery,\nand systemic therapy) might now render adjuvant\nradiotherapy immediately after breast-conserving surgery\nto be optional for an even larger, identifiable subgroup of\npatients who are not currently given this option.10\nIn summary, efforts to minimise toxicity and burden\nof treatment are increasingly important in an era of\nfalling recurrence risks. Future generations of women\ndiagnosed with breast cancer will benefit not only from\nthe findings of the IMPORT LOW trial itself but also from\nthe advances that will build on its foundational efforts.\nReshma Jagsi\nDepartment of Radiation Oncology, University of Michigan,\nAnn Arbor, MI 48109\u20135010, USA\nrjagsi@med.umich.edu\nI have received grants from the National Institutes of Health (R01 and P01),\nthe Doris Duke Foundation, and the Greenwall Foundation.\nCopyright \u00a9 The Author(s). Published by Elsevier Ltd. This is an Open Access\narticle under the CC BY-NC-ND 4.0 license.\n1 Coles CE, Griffin CL, Kirby AM, et al, on behalf of the IMPORT Trialists.\nPartial-breast radiotherapy after breast conservation surgery for patients\nwith early breast cancer (UK IMPORT LOW trial): 5-year results from a\nmulticentre, randomised, controlled, phase 3, non-inferiority trial.\nLancet 2017; published online Aug 2. http://dx.doi.\norg/10.1016/S0140-6736(17)31145-5.\n2 Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effect of\nradiotherapy after breast-conserving surgery on 10-year recurrence and\n15-year breast cancer death: meta-analysis of individual patient data for\n10801 women in 17 randomised trials. Lancet 2011; 378: 1707\u201316.\n3 Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women\nafter radiotherapy for breast cancer. N Engl J Med 2013; 368: 987\u201398.\n4 Taylor C, Correa C, Duane FK, et al, for the Early Breast Cancer Trialists\u2019\nCollaborative Group. Estimating the risks of breast cancer radiotherapy:\nevidence from modern radiation doses to the lungs and heart and from\nprevious randomized trials. J Clin Oncol 2017; 35: 1641\u201349.\n5 Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results\nfrom RAPID: a randomized trial of accelerated partial breast irradiation\nusing three-dimensional conformal external beam radiation therapy.\nJ Clin Oncol 2013; 31: 4038\u201345.\nComment\n1012 www.thelancet.com Vol 390 September 9, 2017\nIrrespective of variations across geography, culture,\nand socioeconomic status, paediatric surgery differs\nfrom other surgical subspecialties. Children are not\nsmall adults. Surgery for infants and children is typically\nundertaken for congenital, rare, and complex conditions\nand the consequences of both the condition and its\ntreatment can affect that individual for life. Above all,\nthe surgical outcome needs to stand the test of time.\nOur Lancet Series papers in this issue on advances in\npaediatric urology1\n and gastroenterology2\n highlight the\ntransition of paediatric surgery from a focus on shortterm patient survival to evidence and innovations\nfor long-term quality of life globally. We believe the\nlessons and challenges have wide implications and offer\ninsights into how knowledge gaps can be filled and new\ntreatments designed.\nMost paediatric surgery requires general anaesthesia and\nconcern about anaesthetic agents harming the developing\nbrain has been raised by some experimental animal\nstudies. The 2016 US Food and Drug Administration\u2019s\nwarning about possible neurodevelopmental effects of\nanaesthetic and sedative drugs in infants younger than\n3 years and in the fetus during the third trimester should,\nhowever, be interpreted with caution.3\n Evidence of harm\nin human beings is inconclusive and, reassuringly, a\nrandomised controlled trial4\n has shown no mediumterm adverse neurodevelopmental effects after a single\ngeneral anaesthetic during infancy. Nevertheless, the\nlong-term outcome of repeated or lengthy anaesthetic\nexposure, especially in more vulnerable subgroups such\nas premature infants, remains unknown. This potential\nrisk of anaesthesia in infancy has created a dilemma about\nwhether to delay the timing of surgery until after the age\n3 years for elective conditions such as hypospadias and\ncraniofacial anomalies in which early correction can confer\nfunctional and psychocosmetic benefits.5\nSurgical decisions made in infancy and childhood\nhave even more profound effects on adult life in the\nmanagement of some disorders of sexual development\n(DSD). In the past, decisions about genital surgery and\nassignation of gender were made during infancy and\nremained a compact between the surgical team and\nthe parents and did not account for underlying ethical\nimplications related to the exclusion of patient\u2019s choice.\nSurgeons are now more aware of the problems arising\nfrom surgery for DSD in infancy. For example, early\nreduction clitoroplasty for enlarged clitoris in female\nDSD can compromise later sexual function,6\n and often\nleads to major concerns about gender identity, body\nhabitus, and psychosexual functioning.7\n Although\nthe exact timing of reconstructive surgery remains\ncontroversial, common practice follows the Chicago\nDSD Consensus guidelines.8 Ethical considerations also\naffect surgical management for other conditions such\nas total intestinal aganglionosis in which surgery results\nin a major health burden of life-long total parenteral\nnutrition.9\n When parental wishes and surgical opinions\ndiffer, for example in end-of-life decisions for multiple\nanomalies, the medical community has to be prepared\nfor ethical, legal, and public debate.\nQuality of life in adults with DSD is also affected\nby hormonal replacement, issues with fertility, an\nincreased risk of malignancy, and personal, family, and\ncultural perceptions of \u201cnormal\u201d sex development.7\nMany adults with complex anorectal malformations\nsimilarly experience sexual dysfunction and more than\n50% of children with such congenital malformations\nneed special education.10\u201312 In terms of increased risk\nof malignancy, there can be a predisposition to laterlife malignancy inherent in the condition (eg, DSD,\nundescended testes, or choledochal cysts),13 or the actual\nnature of the surgical reconstruction can predispose\nLong-term implications and global impact of paediatric surgery\n6 NSABP B-39, RTOG 0413: a randomized phase III study of conventional\nwhole breast irradiation versus partial breast irradiation for women with\nstage 0, I, or II breast cancer. Clin Adv Hematol Oncol 2006; 4: 719\u201321.\n7 Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation\nusing intensity-modulated radiotherapy versus whole breast irradiation:\n5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer\n2015; 51: 451\u201363.\n8 Hughes KS, Schnaper LA, Berry D, et al, for the Cancer and Leukemia Group B,\nRadiation Therapy Oncology Group, and Eastern Cooperative Oncology Group.\nLumpectomy plus tamoxifen with or without irradiation in women 70 years of\nage or older with early breast cancer. N Engl J Med 2004; 351: 971\u201377.\n9 Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, on behalf of the\nPRIME II investigators. Breast-conserving surgery with or without\nirradiation in women aged 65 years or older with early breast cancer\n(PRIME II): a randomised controlled trial. Lancet Oncol 2015;\n16: 266\u2013273.\n10 Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights:\nbreast cancer, version 1\u00b72017. J Natl Compr Canc Netw 2017; 15: 433\u201351.\nSee Editorial page 1006\nSee Series pages 1061 and 1072\nAmelie-Benoist/BSIP/Science Photo Library "
    }
  ],
  "rubrics": [
    "The response should be based only on information found in the following text: \"1010 www.thelancet.com Vol 390 September 9, 2017\r\nGreat improvements in the therapeutic ratio of cancer treatment can result from innovative approaches that maintain tumour control benefits while lowering treatment-associated morbidity. The IMPORT LOW trial by Charlotte Coles and colleagues1 in The Lancet is a high-quality randomised trial of treatment de-escalation in the multidisciplinary management of breast cancer. Numerous trials and their meta-analyses have established that after breast-conserving surgery, radiotherapy cuts the risk of recurrence by half and reduces breast cancer mortality.2 However, this treatment can also result in serious morbidity due to the incidental irradiation of normal tissues, including the heart, lung, and normal breast.3,4 Partial-breast irradiation reduces the dose to normal tissues by treating only the region surrounding the tumour bed (the site of most local failures) rather than the traditional radiotherapeutic target (the whole breast). By reducing the volume of tissue irradiated, particularly when using advanced techniques that allow highly conformal dose distributions, the number of treatments needed could be reduced by allowing higher doses per treatment fraction than conventionally administered to the whole breast. Indeed, many trials have investigated or are investigating the simultaneous reduction in the treatment field and increased radiation dose per fraction in an attempt to reduce not only toxicity but also the burden from multiple repeated treatments.5\u20137 By contrast, IMPORT LOW used a relatively simple technique to reduce the volume of treatment, while holding radiation dose and fractionation constant. The control group received a whole-breast regimen of 40 Gy radiotherapy daily in 15 fractions. The experimental groups had treatment in the vicinity of the tumour bed Early-stage breast cancer: falling risks and emerging options immunosuppression regimens vary depending on the organ. It is unclear how these tissues will reject, how rejection with the same dose and fractionation (partial-breast group) and this treatment with the addition of 36 Gy on the remainder of the whole breast (reduced-dose group). Notably, their approach differs from the more highly conformal approach to partial-breast irradiation that is actively being investigated in other trials. Treatment in IMPORT LOW involved simple forward planning using standard medial and lateral tangential beams reduced in length. This design allows the trial to answer the pure question of whether a reduction in radiation field is safe, with findings that can be applied to many settings, including those with low availability of resources or lower technological capability. The trial shows non-inferiority, with remarkably low estimates of local relapse at 5 years (1\u00b71% [95% CI 0\u00b75\u20132\u00b73] of patients in the control group, 0\u00b72% [0\u00b702\u20131\u00b72] in the reduced-dose group, and 0\u00b75% [0\u00b72\u20131\u00b74] in the partialbreast group). Serious consequences of radiotherapy were uncommon; establishing the effect of irradiating reduced volumes of tissues on endpoints such as cardiac events or second malignancy will probably ultimately require observational comparative effectiveness analyses or individual patient-level meta-analyses of the multiple trials investigating partial-breast irradiation. Still, because the trial laudably included assessment of patient-reported outcomes, it was possible for IMPORT LOW to show that partial-breast treatment reduced patient-reported changes in breast appearance, providing support for the idea that treatment de-escalation in some women is not only safe, but might reduce toxicity. The findings of the trial should, however, only be generalised to women similar to those actually enrolled: women aged 50 years or older with small, unifocal, non-lobular invasive carcinoma resected with non-cancerous tissue margins of 2 mm or more. Most of the women had received endocrine therapy whereas few had received chemotherapy. Most patients enrolled were node negative, and the authors themselves caution against generalising the results of this trial to node-positive patients. Ongoing research regarding radiotherapy de-escalation is still crucial. Even 15 fractions of partial-breast radiotherapy is burdensome and has toxicity risks. Mature data from trials investigating partial-breast regimens that can be administered more efficiently are therefore important, as are trials seeking to identify patients who might safely forego radiotherapy altogether. Indeed, perhaps the most striking finding of IMPORT LOW is not simply that of non-inferiority but rather the extremely low absolute recurrence rates observed across all groups, which were markedly lower than in historical trials.2 Although previous trials have not identified a subgroup of women in whom adjuvant radiotherapy might safely be omitted altogether, with the exception of older women with small hormone-sensitive tumours,8,9 the remarkably low recurrence rates observed in this trial prompt yet again the question of whether some other patients might also reasonably omit radiotherapy. Although longer follow-up is needed, particularly in patients with favourable disease whose recurrences might develop late, the findings of IMPORT LOW support ongoing efforts in the UK, the USA, and beyond that aim to establish whether improvements in other disciplines (eg, imaging, pathology, surgery, and systemic therapy) might now render adjuvant radiotherapy immediately after breast-conserving surgery to be optional for an even larger, identifiable subgroup of patients who are not currently given this option.10 In summary, efforts to minimise toxicity and burden of treatment are increasingly important in an era of falling recurrence risks. Future generations of women diagnosed with breast cancer will benefit not only from the findings of the IMPORT LOW trial itself but also from the advances that will build on its foundational efforts.\u201d",
    "The response should be no longer than 250 words.",
    "The response should follow all medical terminology (such as \u201cunifocal,\u201d \u201cnon-lobular\u201d and \u201cnode-negative\u201d) with a brief contextual explanation. For example, \"unifocal\" means originating from a single site, \"non-lobular\" means not related to the breast's milk-producing glands, and \"node-negative\" means not found in the lymph nodes.",
    "The response should state that due to age, the 49-year-old Patient A is ineligible for the IMPORT LOW trial which consists of women aged 50 years or older.",
    "The response should state that patient A's non-age-related qualifications, \"unifocal, non-lobular invasive carcinoma with a non-cancerous tissue margin of 2.01mm,\" are in alignment with the trial per \"small, unifocal, non-lobular invasive carcinoma resected with non-cancerous tissue margins of 2 mm or more.\u201d",
    "The response should address Patient B\u2019s concerns about relapse rates for study participants by stating that the participants\u2019 5-year relapse rates are between 0% and 2%.",
    "The response should state, for patient B, that cardiac events were uncommon but require further study, per \"Serious consequences of radiotherapy were uncommon; establishing the effect of irradiating reduced volumes of tissues on endpoints such as cardiac events or second malignancy will probably ultimately require observational comparative effectiveness analyses or individual patient-level meta-analyses of the multiple trials investigating partial-breast irradiation.\"",
    "The response should explain that Patient C\u2019s prior full radiation treatment may render her unsuitable for the IMPORT LOW trial. For example, it should mention that the focus of the trial was on reduced radiation therapies and that repeated radiation in the same areas could create safety concerns.",
    "The response should be formatted in an orderly and easily comprehensible fashion. For example, it could use numbered lists or bullet points.",
    "The response should include an introduction briefly summarizing its key points.",
    "The response should use a clinical tone appropriate for a medical journal. For example, it should present facts without emotion or judgement.",
    "The response should discuss all three patients (Patient A, Patient B, and Patient C).",
    "The response should discuss Patient A, Patient B and Patient C individually. For example, it should divide its discussion of each patient with formatting such as bullet points or bolded headers.",
    "The response should not offer an opinion on whether patients should enroll in the trial. For example, it should not say things like, \u201cPatient A will be an excellent candidate for the trial once she turns 50 and should definitely consider it.\u201d",
    "The response should address that Patient A will be 50 within 6 months when discussing eligibility for the IMPORT LOW trial which is for those age 50 and older. For example, it should say that while the patient is currently ineligible, the trial might be an option once she turns 50."
  ],
  "metadata": {
    "task_id": "76cc5463-e20c-48b5-ba99-32afec279fa2",
    "context_id": "784569a1-bc4b-4e3b-8b9e-f92397c7c0c7",
    "context_category": "Domain Knowledge Reasoning",
    "sub_category": "Healthcare"
  }
}